succeeded in inducing bnAbs. Recent progress in understanding the immunobiology of bnAbs and founder viruses, 9 and insights from structural studies of bnAbs 10, 11 have led to new ways to think about bnAb development, and led to new strategies for bnAb induction.
Hraber et al. 12 demonstrated that 50% of chronically HIV-1 infected individuals develop plasma neutralization breadth for approximately 50% of HIV-1 global strains over several years of infection.
Moreover, recent success in establishing and monitoring large cohorts of HIV-infected individuals including those studied from transmission though bnAb development, 5, 13, 14 and advances in antibody isolation and B cell repertoire analysis have enabled the identification of dozens of new bnAbs from multiple HIV-1 infected adults [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] and children. 28, 29 In addition, more than one bnAb lineage can occur in the same individual. 16, 30 In HIV-1 infected adults, plasma levels of bnAbs usually develop after 2-4 years of infection. However, in children, examples of plasma bnAb breath occurring within the first year of HIV-1 infection have been reported. 28, 29 Because many bnAbs have unusual traits of high levels of somatic mutations, long third heavy chain complementarity regions (CDR H3s) and/or poly-or auto-reactivity, it has been postulated that bnAb maturation is disfavored due to control by host tolerance mechanisms. 31, 32 Thus, if the key events of virus Env and bnAb lineage evolution could be defined in the setting of HIV-1 infection, then a path to successful induction of bnAbs could be the recapitulation of these events in the setting of vaccination.
Here, we review progress made to date in understanding pathways of bnAb induction in the setting of infection and vaccination, discuss B cell lineage cooperation in bnAb ontogeny and review new strategies of vaccine design.
| CHARACTERISTICS OF BROADLY NEUTRALIZING ANTIBODIES
There are six known viral Env regions targeted by bnAbs: the CD4-binding site (CD4bs) 16, 17, 26, 27, [33] [34] [35] ; the gp120 V1V2-glycan region 14, 15, 19 ; the V3-glycan region 20, [23] [24] [25] 28 ; the interface between gp120 and gp41 Env glycoproteins, 36 the gp41 fusion domain, 37 and the gp41 Env membrane proximal external region (MPER) 38, 39 (Williams L. D. and Haynes B. F., unpublished) ( Figure 1 ). In this review, we will discuss three bnAb specificities that have been characterized in antibody-virus co-evolution studies: the CD4 binding site, the V3-glycan and the V1V2-glycan regions.
| CD4-binding site broadly neutralizing antibodies
The functional integrity of the CD4bs is required for virus infectivity and therefore its structure is highly conserved. 40 CD4bs bnAbs have been isolated from multiple HIV-1 infected individuals, suggesting that their induction is relatively common and therefore an achievable goal in the setting of vaccination. Moreover, CD4bs bnAbs isolated F I G U R E 1 Sites of vulnerability on the HIV-1 Env glycoprotein spike. The structure of a HIV-1 prefusion trimer (PDB: 4TVP) is displayed with gp120 and gp41 protomers colored in blue and beige respectively. Epitope mapping of multiple broadly neutralizing antibodies has identified six sites of vulnerability of the HIV-1 Env glycoprotein: the V1V2 loop (red); the base of the V3 loop (green); the CD4-binding site (orange); the interface between gp120 and gp41 proteins (magenta); the fusion peptide region (yellow), and the membrane proximal external region (MPER, brown). Both the V1V2 and the V3 loop bnAb epitopes include direct contact with glycans. The MPER near the base of the Env trimer, the transmembrane and the cytoplasmic domains have only limited structural information and are highlighted for reference (red and sand cylinders and green sticks). Figure derived from structure described by Pancera et al.
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from infected individuals share similar V H and V L gene characteristics suggesting commonalities in their maturation pathways that could be recapitulated by a B-cell lineage design approach in multiple individuals. 41 
| V1V2-glycan broadly neutralizing antibodies
The V1V2-glycan bnAb class was the first of the new generation of bnAbs discovered. 14 
| ANTIBODY-VIRUS CO-EVOLUTION

| CD4-binding site CDR H3-binder bnAb development
We first defined the detailed nature of the arms race between HIV-1 and a bnAb with our studies of the co-evolution of the TF virus and the CH103 CDR H3-binder CD4bs bnAb B cell lineage in the African individual CH505 during the first 3 years of infection.
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The UCA of the CH103 bnAb lineage bound the TF HIV-1 envelope glycoprotein as gp140 and gp120 Envs, and early CH103 lineage antibodies only slowly escaped autologous virus variants. In particular, the N280 loop D mutations observed in the evolving autologous viruses were predicted to disrupt this H-bond network. 
| V3-glycan broadly neutralizing antibody development
The ; and (iii) the UCA of the V3-glycan lineages did not neutralize or bind autologous TF suggesting the hypothesis that V3-glycan bnAb lineages may arise in response to altered forms of the Env protein.
| V1V2-glycan broadly neutralizing antibody development
The V2 glycan bnAb lineage VRC26 was isolated from an African individual, CAP256, followed from the time of infection to bnAb development. 19 Recombination between primary and superinfecting viruses led to extraordinary diversity in autologous virus evolution with accelerated diversification, including sampling of different amino acids at position 169, and the preferred route of escape of the autologous virus from the CAP256-VRC26 lineage was a rare K169I mutation. 64 Non-bnAbs in the lineage followed two evolutionary pathways: they either displayed limited evolution and did not tolerate diversity at position 169
("dead-end sublineage") or acquired somatic mutation levels comparable to those of the bnAbs but displayed a more restricted, strainspecific neutralization of autologous quasispecies variants ("off-track antibodies"). 64 Conversely, in a mechanism that closely resembled CD4bs CH235 bnAb evolution, 
| Intrinsic mutability of immunoglobulin genes and accumulation of somatic mutations
The evolution of the CH235 CD4 mimic CD4bs antibody lineage proceeded in a manner that depended less on antigen selection and more on intrinsic mutability of the V H 1 gene, since mutations accumulated at positions that also mutate frequently in non-HIV-1 antibodies.
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Similarly, amino acid substitutions in CH235 at these positions were also frequently seen in non-HIV-1 antibodies. 16 These commonalities extended to other V H 1-2*02 and V H 1-46 CD4 mimic bnAbs 16 and V H 1-2*02 V3-glycan bnAbs (Bonsignori M and Haynes B. F., unpublished), implying that intrinsic mutability at specific nucleotide sites is a more general biological phenomenon that plays a role in dictating the degree of somatic mutations. 16, 32, 65, 66 We dissected the role of intrinsic mutability and activation- All four mutations involved sites of intrinsic mutability. While three mutations occurred at AID hotspots and resulted in both positional and identity conformity to non-HIV-1-reactive antibodies, the fourth mutation occurred at an AID cold spot (Bonsignori M and Haynes B.
F., unpublished). This improbable Env mutation had two effects: (i) it
disrupted an overlapping AID hotspot within the same codon and (ii) it introduced a new AID cold spot at the same position, thus fixing the improbable mutation throughout lineage maturation (Bonsignori M and Haynes B. F., unpublished). All subsequent mutations at sites of intrinsic mutability throughout the DH270 lineage maturation occurred at AID hotspots. The functional relevance of the improbable mutation in the DH270 bnAb lineage is that it was sufficient and necessary for neutralizing activity (Bonsignori M and Haynes B. F., unpublished).
Thus, the analysis of bnAb lineage evolution in the context of AIDinduced intrinsic mutability is a powerful tool to identify which mutations are both critical to maintain lineage evolution on its path toward neutralization breadth and less likely to occur, so that immunogens can be designed to specifically target these rare mutations and ensure their selection through lineage maturation 16 (Bonsignori M and Haynes B. F., unpublished). This observation highlights the challenges of identifying suitable immunogens that will stimulate appropriate germline B cells as an essential early event in bnAb development.
| NEUTRALIZATION ASSESSMENT OF BNAB LINEAGE DEVELOPMENT
| B CELL LINEAGE IMMUNOGEN DESIGN
The HIV-1 vaccine development field has realized that immunization with a single HIV envelope protein will not be successful at inducing bnAbs. 
| ENV REGIMENS THAT DERIVE FROM ANTIBODY-VIRUS CO-EVOLUTION STUDIES
We 
| Immunogen design for CD4 mimicking CD4 binding site bnAb immunogens
The second bnAb lineage that occurred in CH505 was a V H 1-46, CD4-mimicking CD4bs bnAb lineage that over 6 years developed extraordinary potency and breadth ( Figure 8A ). Here, an extensive set of approximately 100 CH505 evolved autologous Envs were produced as both gp120s and/or gp140s and tested for binding to both CH103 
| Immunogen design for V3-glycan bnAb site immunogens
As noted above, neither we (Bonsignori M. and Haynes B. 
| CONCLUSIONS
Work over the past 10 years has demonstrated that bnAb B cell lineages are disfavored, are in many cases controlled by tolerance or other improbable events, and will require targeting of specific B cell lineages with sequential immunogens to achieve induction of bnAbs. It has become apparent that to induce bnAbs several conditions must be optimized. Second, the sequence of Envs used will need to be optimized. Here,
we have described some of the considerations that are used from F I G U R E 9 Immunogen design for V3-glycan broadly neutralizing antibodies. An immunization strategy to elicit DH270-like V3 glycan bnAbs is composed of three steps. First, prime with an immunogen that binds to the UCA. We have identified a synthetic Man 9 V3 glycopeptide as a candidate immunogen (Bonsignori M., Alam S. M. and Haynes B. F., unpublished). Clonal differentiation subsequent to priming will lead to the introduction of somatic mutations, including improbable mutations critical for clonal maturation toward neutralization breadth (green). Second, boosting with an immunogen that engages of DH270.IA4-like antibodies and select for the these improbable mutations, providing an evolutionary advantage to a subdominant response. Third, boost with Env immunogens with longer V1 loops, as the ability to neutralize viruses with longer V1 loops was correlated with broader neutralization in the DH270 lineage (Bonsignori M, Korber B. T. and Haynes B.F., unpublished)
antibody-virus co-evolution studies. New bioinformatics tools have been developed to more precisely select Envs for immunization. Third, the adjuvant to be used is critical, and will need to selectively drive high levels of T follicular helper cells (T fh ) and not activate or induce low levels of T regulatory cells (T reg ) in germinal centers. 103, 104 Finally, it has become clear that host controls of full bnAb lineage maturation are preventing the full development of bnAbs in the setting of vaccination. Some bnAb types such as gp41 MPER bnAbs (2F5, 4E10, DH511 and 10E8) must have hydrophobic CDR H3s for binding to the virion membrane, and bnAb precursors with these characteristics are either deleted in bone marrow or became anergic in the periphery. 98, [105] [106] [107] [108] [109] Other bnAb types such as CD4bs antibodies are either not deleted in bone marrow or less so than gp41 antibodies, but rather antibody poly-reactivity or auto-reactivity is acquired later in bnAb B cell lineage maturation. 17 Thus, for many types of bnAbs, the concept has arisen that a component of a successful vaccine for induction of bnAb B cell lineages to full neutralization breadth will be the formulation of Env vaccines in adjuvants that promote a profile of the immune system in bnAb development with high T fh and low T reg , and promote repeated rounds of affinity maturation in germinal centers. 103, 104 In addition, HIV-1 infection induces autoimmune manifestations in approximately 50% of individuals, and those HIV-1 infected individuals that make bnAbs have higher frequencies of autoantibodies than those that do not make bnAbs, indicating that bnAbs arise in the setting of HIV-1-induced loosening of immune tolerance controls. 103 Thus, depending on the bnAb lineage, adjuvants or other inhibitors of immune tolerance controls may need to be utilized to achieve full bnAb maturation.
The path to bnAb induction remains difficult, and more than one bnAb type will need to be induced by a successful vaccine to prevent TF escape following transmission. Nonetheless, the recognition that induction of bnAbs is dependent on complex virus Envantibody interactions and is under host controls has paved the way for design of new sequential immunogens that have the potential to overcome the hurdles standing in the way of bnAb induction.
